vs

Side-by-side financial comparison of Offerpad Solutions Inc. (OPAD) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

Offerpad Solutions Inc. is the larger business by last-quarter revenue ($114.1M vs $69.8M, roughly 1.6× RIGEL PHARMACEUTICALS INC). On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs -34.5%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs -36.8%).

Offerpad Solutions Inc is a prominent U.S. proptech firm focused on simplifying residential real estate transactions. Operating under the iBuyer model, it purchases homes directly from sellers, conducts required renovations, and resells properties to buyers. It also provides supporting services including mortgage assistance, title services, and flexible moving options for clients across dozens of U.S. states.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

OPAD vs RIGL — Head-to-Head

Bigger by revenue
OPAD
OPAD
1.6× larger
OPAD
$114.1M
$69.8M
RIGL
Growing faster (revenue YoY)
RIGL
RIGL
+55.7% gap
RIGL
21.2%
-34.5%
OPAD
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
-36.8%
OPAD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OPAD
OPAD
RIGL
RIGL
Revenue
$114.1M
$69.8M
Net Profit
$268.1M
Gross Margin
7.0%
91.5%
Operating Margin
33.2%
Net Margin
384.0%
Revenue YoY
-34.5%
21.2%
Net Profit YoY
49.1%
1769.2%
EPS (diluted)
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPAD
OPAD
RIGL
RIGL
Q4 25
$114.1M
$69.8M
Q3 25
$132.7M
$69.5M
Q2 25
$160.3M
$101.7M
Q1 25
$160.7M
$53.3M
Q4 24
$174.3M
$57.6M
Q3 24
$208.1M
$55.3M
Q2 24
$251.1M
$36.8M
Q1 24
$285.4M
$29.5M
Net Profit
OPAD
OPAD
RIGL
RIGL
Q4 25
$268.1M
Q3 25
$-11.6M
$27.9M
Q2 25
$-10.9M
$59.6M
Q1 25
$-15.1M
$11.4M
Q4 24
$-17.3M
$14.3M
Q3 24
$-13.5M
$12.4M
Q2 24
$-13.8M
$-1.0M
Q1 24
$-17.5M
$-8.2M
Gross Margin
OPAD
OPAD
RIGL
RIGL
Q4 25
7.0%
91.5%
Q3 25
7.0%
93.2%
Q2 25
8.9%
95.6%
Q1 25
6.5%
91.7%
Q4 24
6.1%
89.9%
Q3 24
8.2%
85.5%
Q2 24
8.7%
92.4%
Q1 24
7.9%
93.1%
Operating Margin
OPAD
OPAD
RIGL
RIGL
Q4 25
33.2%
Q3 25
-5.1%
40.9%
Q2 25
-4.9%
60.1%
Q1 25
-7.2%
23.9%
Q4 24
-7.8%
28.9%
Q3 24
-4.3%
25.4%
Q2 24
-3.9%
1.2%
Q1 24
-4.8%
-23.6%
Net Margin
OPAD
OPAD
RIGL
RIGL
Q4 25
384.0%
Q3 25
-8.7%
40.2%
Q2 25
-6.8%
58.6%
Q1 25
-9.4%
21.5%
Q4 24
-9.9%
24.9%
Q3 24
-6.5%
22.5%
Q2 24
-5.5%
-2.8%
Q1 24
-6.1%
-27.9%
EPS (diluted)
OPAD
OPAD
RIGL
RIGL
Q4 25
$14.11
Q3 25
$-0.37
$1.46
Q2 25
$-0.39
$3.28
Q1 25
$-0.55
$0.63
Q4 24
$-0.64
$0.82
Q3 24
$-0.49
$0.70
Q2 24
$-0.50
$-0.06
Q1 24
$-0.64
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPAD
OPAD
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$26.5M
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$38.2M
$391.5M
Total Assets
$154.8M
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPAD
OPAD
RIGL
RIGL
Q4 25
$26.5M
$155.0M
Q3 25
$31.0M
$137.1M
Q2 25
$22.6M
$108.4M
Q1 25
$30.8M
$77.1M
Q4 24
$43.0M
$77.3M
Q3 24
$48.5M
$61.1M
Q2 24
$56.9M
$49.1M
Q1 24
$68.5M
$49.5M
Total Debt
OPAD
OPAD
RIGL
RIGL
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
OPAD
OPAD
RIGL
RIGL
Q4 25
$38.2M
$391.5M
Q3 25
$39.9M
$117.6M
Q2 25
$24.5M
$81.9M
Q1 25
$34.2M
$18.6M
Q4 24
$47.7M
$3.3M
Q3 24
$64.7M
$-14.6M
Q2 24
$77.6M
$-29.9M
Q1 24
$88.1M
$-31.7M
Total Assets
OPAD
OPAD
RIGL
RIGL
Q4 25
$154.8M
$513.6M
Q3 25
$223.5M
$242.5M
Q2 25
$268.0M
$206.7M
Q1 25
$274.5M
$176.0M
Q4 24
$313.1M
$164.0M
Q3 24
$338.5M
$139.4M
Q2 24
$406.6M
$128.4M
Q1 24
$369.7M
$126.5M
Debt / Equity
OPAD
OPAD
RIGL
RIGL
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OPAD
OPAD
RIGL
RIGL
Operating Cash FlowLast quarter
$66.8M
$22.0M
Free Cash FlowOCF − Capex
$65.7M
FCF MarginFCF / Revenue
57.6%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OPAD
OPAD
RIGL
RIGL
Q4 25
$66.8M
$22.0M
Q3 25
$40.0M
$24.0M
Q2 25
$-13.5M
$30.5M
Q1 25
$-10.2M
$-893.0K
Q4 24
$20.8M
$14.5M
Q3 24
$39.6M
$21.7M
Q2 24
$-54.4M
$302.0K
Q1 24
$2.4M
$-5.0M
Free Cash Flow
OPAD
OPAD
RIGL
RIGL
Q4 25
$65.7M
Q3 25
Q2 25
$-13.6M
Q1 25
$-11.2M
Q4 24
$15.4M
Q3 24
$38.7M
Q2 24
$-54.4M
Q1 24
$2.0M
FCF Margin
OPAD
OPAD
RIGL
RIGL
Q4 25
57.6%
Q3 25
Q2 25
-8.5%
Q1 25
-7.0%
Q4 24
8.9%
Q3 24
18.6%
Q2 24
-21.7%
Q1 24
0.7%
Capex Intensity
OPAD
OPAD
RIGL
RIGL
Q4 25
0.9%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
0.6%
Q4 24
3.1%
Q3 24
0.4%
Q2 24
0.0%
Q1 24
0.1%
Cash Conversion
OPAD
OPAD
RIGL
RIGL
Q4 25
0.08×
Q3 25
0.86×
Q2 25
0.51×
Q1 25
-0.08×
Q4 24
1.01×
Q3 24
1.75×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons